Skip to Main Content

Paper Details

Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 â¿¥50%, but unanswered questions remain.
Ann Transl Med
8
2019
Author NameAffiliation
Dexiang GaoSchool of Medicine and Colorado School of Public Health, University of Colorado Denver
  • 1 - 1

Datasets

Release 1.2